Professor Raul Santos (University of São Paulo, Brazil) discusses PCSK9 inhibition and lower extremity peripheral arterial disease.
Typically undertreated, what do the new findings from FOURIER mean for these very high risk patients? |
Professor François Mach (Geneva University Hospitals, Switzerland) discusses PCSK9 inhibition and cognitive function.
What do the latest publications add to the evidence? |
